VitalStone Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

VitalStone Financial’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-86	Closed	-$2K	–	476
2023 Q3	$2K	Buy	+86	New	+$2.34K	﹤0.01%	351

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

VitalStone Financial's ACAD Position: Q4 2023 in Review

VitalStone Financial sold out of Acadia Pharmaceuticals (ACAD) in Q4 2023, closing a stake of 86 shares — an estimated $2K sold.

VitalStone Financial first reported a position in ACAD in Q3 2023 and held it in 1 quarter. The position peaked at $2K in Q3 2023. 276 funds tracked by Wall St. Rank hold ACAD as of Q4 2023.

VitalStone Financial reported no remaining Acadia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
VitalStone Financial sold 86 Acadia Pharmaceuticals shares in Q4 2023, an estimated $2K.
VitalStone Financial first reported a position in Acadia Pharmaceuticals in Q3 2023 and held it in 1 quarter.
VitalStone Financial's Acadia Pharmaceuticals position peaked at $2K in Q3 2023.
276 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2023.

Based on VitalStone Financial's 13F filing for Q4 2023, filed 14 Feb 2024.